Aggressive blood pressure reduction and renin-angiotensin system blockade in chronic kidney disease: time for re-evaluation? (Q38139240)

29 August 2017

title

Aggressive blood pressure reduction and renin-angiotensin system blockade in chronic kidney disease: time for re-evaluation? (English)

1 reference

chronic renal insufficiency

29 August 2017

main subject

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24048382%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Luis Miguel Ruilope

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24048382%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

author name string

Pantelis A Sarafidis

series ordinal

1

1 reference

29 August 2017

language of work or name

English

0 references

publication date

18 September 2013

1 reference

29 August 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24048382%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

volume

85

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24048382%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24048382%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

page(s)

536-546

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24048382%20AND%20SRC:MED&resulttype=core&format=json

Microalbuminuria and chronic kidney disease as risk factors for cardiovascular disease

13 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.355

7 January 2021

Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.355

7 January 2021

World Kidney Day 2011: protect your kidneys, save your heart

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.355

7 January 2021

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE>

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.355

7 January 2021

2007 Guidelines for the Management of Arterial Hypertension

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.355

7 January 2021

Standards of medical care in diabetes--2010.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.355

7 January 2021

ACCORD and Risk-Factor Control in Type 2 Diabetes

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.355

7 January 2021

Use of a single target blood pressure level in type 2 diabetes mellitus for all cardiovascular risk reduction: comment on "intensive and standard blood pressure targets in patients with type 2 diabetes mellitus"

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.355

7 January 2021

Standards of medical care in diabetes--2013

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.355

7 January 2021

Antihypertensive therapy in the presence of proteinuria

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.355

7 January 2021

Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLH

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.355

7 January 2021

Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.355

7 January 2021

Cardiorenal end points in a trial of aliskiren for type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.355

7 January 2021

The Effects of Dietary Protein Restriction and Blood-Pressure Control on the Progression of Chronic Renal Disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.355

7 January 2021

Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.355

7 January 2021

Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.355

7 January 2021

The effect of a lower target blood pressure on the progression of kidney disease: long-term follow-up of the modification of diet in renal disease study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.355

7 January 2021

Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.355

7 January 2021

Intensive Blood-Pressure Control in Hypertensive Chronic Kidney Disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.355

7 January 2021

Effect of intensive blood pressure control on the course of type 1 diabetic nephropathy. Collaborative Study Group

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.355

7 January 2021

Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.355

7 January 2021

Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.355

7 January 2021

Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.355

7 January 2021

Chronic kidney disease awareness, prevalence, and trends among U.S. adults, 1999 to 2000.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.355

7 January 2021

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.355

7 January 2021

Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.355

7 January 2021

Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.355

7 January 2021

Trends in blood pressure control in patients with type 2 diabetes: data from the Swedish National Diabetes Register (NDR).

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.355

7 January 2021

Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.355

7 January 2021

Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.355

7 January 2021

Effects of intensive blood-pressure control in type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.355

7 January 2021

Blood pressure targets in subjects with type 2 diabetes mellitus/impaired fasting glucose: observations from traditional and bayesian random-effects meta-analyses of randomized trials.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.355

7 January 2021

Effects of intensive blood pressure reduction on myocardial infarction and stroke in diabetes: a meta-analysis in 73 913 patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.355

7 January 2021

Intensive and Standard Blood Pressure Targets in Patients With Type 2 Diabetes Mellitus: Systematic Review and Meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.355

7 January 2021

Current guidelines for using angiotensin-converting enzyme inhibitors and angiotensin II-receptor antagonists in chronic kidney disease: is the evidence base relevant to older adults?

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.355

7 January 2021

Does evidence support renin-angiotensin system blockade for slowing nephropathy progression in elderly persons?

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.355

7 January 2021

The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.355

7 January 2021

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.355

7 January 2021

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.355

7 January 2021

Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.355

7 January 2021

Effects of renin-angiotensin system blockers on renal outcomes and all-cause mortality in patients with diabetic nephropathy: an updated meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.355

7 January 2021

Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.355

7 January 2021

Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.355

7 January 2021

Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.355

7 January 2021

Efficacy and safety of benazepril for advanced chronic renal insufficiency

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.355

7 January 2021

Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.355

7 January 2021

The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.355

7 January 2021

Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.355

7 January 2021

Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.355

7 January 2021

Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in chronic renal disease: safety issues

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.355

7 January 2021

An economic evaluation of the 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of mild-to-moderate hypertension in Greece

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.355

7 January 2021

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.355

7 January 2021

Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.355

7 January 2021

Progression of renal disease--can we forget about inhibition of the renin-angiotensin system?

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.355

7 January 2021

Renoprotective effects of renin-angiotensin-system inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.355

7 January 2021

Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.355

7 January 2021

Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.355

7 January 2021

Additional antiproteinuric effect of ultrahigh dose candesartan: a double-blind, randomized, prospective study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.355

7 January 2021

Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.355

7 January 2021

Optimal dose of lisinopril for renoprotection in type 1 diabetic patients with diabetic nephropathy: a randomised crossover trial

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.355

7 January 2021

Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.355

7 January 2021

Dual blockade of the renin-angiotensin system in diabetic nephropathy: a randomized double-blind crossover study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.355

7 January 2021

Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.355

7 January 2021

Retraction--Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.355

7 January 2021

Telmisartan, ramipril, or both in patients at high risk for vascular events

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.355

7 January 2021

Renin-angiotensin blockade and kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.355

7 January 2021

New clinical concepts after the ONTARGET trial

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.355

7 January 2021

Aliskiren combined with losartan in type 2 diabetes and nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.355

7 January 2021

Aliskiren in combination with losartan reduces albuminuria independent of baseline blood pressure in patients with type 2 diabetes and nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.355

7 January 2021

Impact of baseline renal function on the efficacy and safety of aliskiren added to losartan in patients with type 2 diabetes and nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.355

7 January 2021

Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D).

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.355

7 January 2021

Aldosterone in the development and progression of renal injury

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.355

7 January 2021

ACE inhibition or angiotensin receptor blockade: impact on potassium in renal failure. VAL-K Study Group

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.355

7 January 2021

Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotens

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.355

7 January 2021

Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.355

7 January 2021

Beneficial impact of spironolactone in diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.355

7 January 2021

Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.355

7 January 2021

Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.355

7 January 2021

Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.355

7 January 2021

Prevalence and factors associated with hyperkalemia in predialysis patients followed in a low-clearance clinic.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.355

7 January 2021